Avalyn Pharma Inc. Common Stock
AVLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.14B
Close$
$1.21
95.1% downside
Current Fair Value
95.1% downsideOvervalued by 95.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.14 Billion |
|---|---|
| Enterprise Value | $894.93 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.04 |
| Beta | -1.13 |
| Outstanding Shares | 44,333,094 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -19.97 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 3.08 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.71
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 106.36%▲ 106.36% |
|---|---|
| Total Invested | $1.46B |
| Investors Holding | 95▲ 95.00% |
ESG Score
No data
About Avalyn Pharma Inc. Common Stock
50 employees
CEO: Lyn Baranowski Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis ...